CIK 0001676725 · Large accelerated filer
IDEAYA Biosciences, Inc.
Sign in to watch- Ticker
- IDYA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474268251
- Phone
- 650-443-6209
- Business address
- 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $985,397
- in 1 filing, $985K under 10b5-1 plans
Net −$985,397. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-09 | Kelley Susan L. Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2022-06-09 | Morrison Scott W Director | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2022-06-09 | Stein Jeffrey Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2022-06-09 | Hampton Malcolm Garret Director | Grant or award · Stock Option (right to buy) | +11,000 | 11,000 | ||
| 2022-04-05 | MACKEY CATHERINE J Director | Grant or award · Stock Option (Right to Buy) | +22,000 | 22,000 | ||
| 2022-03-01 | Stone Paul A. SVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +92,500 | 92,500 | ||
| 2022-03-01 | WHITE MICHAEL ANTHONY SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +92,500 | 92,500 | ||
| 2022-03-01 | Hata Yujiro S President and CEO | Grant or award · Stock Option (right to buy) | +260,000 | 260,000 | ||
| 2022-03-01 | Throne Jason SVP, General Counsel | Grant or award · Stock Option (Right to Buy) | −63,750 | 63,750 | ||
| 2021-10-25 | WHITE MICHAEL ANTHONY SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2021-10-04 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise | +1,500 | $11.08 | $17K | 80,289 |
| 2021-10-04 | Dillon Michael P. SVP, Chief Scientific Officer | Sale | −500 | $25.85 | $13K | 79,789 |
| 2021-10-04 | Dillon Michael P. SVP, Chief Scientific Officer | Sale | −1,000 | $26.62 | $27K | 78,789 |
| 2021-10-04 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −1,500 | 23,437 | ||
| 2021-09-08 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise | +7,071 | $4.31 | $30K | 85,860 |
| 2021-09-08 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise | +4,313 | $11.08 | $48K | 90,173 |
| 2021-09-08 | Dillon Michael P. SVP, Chief Scientific Officer | Sale | −11,184 | $27.41 | $307K | 78,989 |
| 2021-09-08 | Dillon Michael P. SVP, Chief Scientific Officer | Sale | −200 | $27.67 | $6K | 78,789 |
| 2021-09-08 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −7,071 | 59,048 | ||
| 2021-09-08 | Dillon Michael P. SVP, Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −4,313 | 24,937 |
Page 9 of 10 · 186 trades